Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yun Beom Sang
Observed names:
Y.B. Sang,
Yun-Beom Sang,
Yunbeom Sang
Institutions:
CHA University Bundang Medical Center,
CHA University
Observed institutions:
Yonsei University,
CHA University Bundang Medical Center,
CHA University,
Yonsei University Health System,
Yonsei Cancer Hospital
ORCID:
0000-0002-1123-6313
Observed ORCID:
0000-0002-1123-6313
OpenAlex ID:
A5068365751
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
2021
·
Chang-Gon Kim
, Yun-Beom Sang
, et al.
·
International Journal of Molecular Sciences
·
80
PDF
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
2022
·
Yun Beom Sang
, Joo-Hang Kim
, et al.
·
Frontiers in Oncology
·
60
PDF
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
2022
·
Yun Beom Sang
, Hannah Yang
, et al.
·
Cancers
·
27
PDF
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
2021
·
Jaekyung Cheon
, Choong-kun Lee
, et al.
·
Therapeutic Advances in Medical Oncology
·
27
PDF
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
2023
·
Young Shin Song
, Hannah Yang
, et al.
·
Liver Cancer
·
24
High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma
2023
·
Youngun Kim
, Hannah Yang
, et al.
·
Journal of Cancer
·
18
PDF
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year
2024
·
Youngun Kim
, Jung Sun Kim
, et al.
·
Cancer Research and Treatment
·
11
Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c- MET Amplification
2022
·
Yun Beom Sang
, Gwangil Kim
, et al.
·
Journal of Clinical and Translational Hepatology
·
11
PDF
677P Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
2023
·
Y.B. Sang
, Y. Kim
, et al.
·
Annals of Oncology
·
4
PDF
Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC).
2021
·
Yunbeom Sang
, Minkyu Jung
, et al.
·
Journal of Clinical Oncology
·
2
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab
2024
·
Yun Beom Sang
, Chaeryoung Lee
, et al.
·
Journal of Clinical Medicine
·
1
PDF
Efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin (GemCis/nab-P) in Korean patients with advanced biliary tract cancers (aBTC): Multicenter retrospective analysis.
2021
·
Jaekyung Cheon
, Choong-kun Lee
, et al.
·
Journal of Clinical Oncology
·
1
Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure
2026
·
Moonki Hong
, Junho Choi
, et al.
·
Therapeutic Advances in Medical Oncology
Clinical characteristics of patients with advanced hepatocellular carcinoma who received long-term treatment with atezolizumab and bevacizumab for more than one year.
2024
·
Youngun Kim
, Beodeul Kang
, et al.
·
Journal of Clinical Oncology
PDF
193P Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
2023
·
Y.B. Sang
, C.R. Lee
, et al.
·
Annals of Oncology
PDF
993P Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
2023
·
H. Chon
, Y.S. Song
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
16
Citation count:
266
H-index:
8
I10-index:
8
Year
Topic
Type